Deciphera Pharmaceuticals, LLC

Deciphera Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 INTREPID Study of Sapablursen in Polycythemia Vera

• Global pivotal Phase 3 study will evaluate the efficacy and safety over a 52-week treatment period • Polycythemia Vera (PV) is a rare and potentially life-threatening hematologic disease with significant persistent unmet need • Sapablursen received Fast Track, Orphan Drug and Breakthrough Therapy…

Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan

Application submitted for manufacturing and marketing approval of ripretinib in Japan for the indication of “gastrointestinal stromal tumor that has progressed following cancer chemotherapy” Ripretinib has significantly prolonged the primary endpoint of progression-free survival compared to placebo…

Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL

– Regulatory submission is based on positive results from the Phase 2 PROSPECT Study — – FDA sets PDUFA Date of December 18, 2026 — OSAKA, Japan & WALTHAM, Mass.--( BUSINESS WIRE )-- Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO:…

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting

● Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin ● Sapablursen was generally safe and well tolerated ● Results support further development of sapablursen in a Phase 3 study OSAKA, Japan &…

Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2025

– Multiple presentations on vimseltinib for the treatment of Tenosynovial Giant Cell Tumor (TGCT), including encore data from the Phase 3 MOTION study presented in an oral session – – Two posters on DCC-3009 in Gastrointestinal Stromal Tumor (GIST) – OSAKA, Japan & WALTHAM, Mass.--( BUSINESS WIRE…

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – OSAKA, Japan & WALTHAM, Mass.--( BUSINESS WIRE )-- Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the…